NZ512981A - Use of pyridazino[4,5-b]indole-1-acetamide derivatives for treating diseases related to the dysfunction of peripheral benzodiazepine receptors - Google Patents

Use of pyridazino[4,5-b]indole-1-acetamide derivatives for treating diseases related to the dysfunction of peripheral benzodiazepine receptors

Info

Publication number
NZ512981A
NZ512981A NZ512981A NZ51298100A NZ512981A NZ 512981 A NZ512981 A NZ 512981A NZ 512981 A NZ512981 A NZ 512981A NZ 51298100 A NZ51298100 A NZ 51298100A NZ 512981 A NZ512981 A NZ 512981A
Authority
NZ
New Zealand
Prior art keywords
pyridazino
indole
dysfunction
benzodiazepine receptors
treating diseases
Prior art date
Application number
NZ512981A
Other languages
English (en)
Inventor
Badia Ferzaz
Jesus Benavides
Frank Marguet
Jacques Froissant
Benoit Marabout
Yannick Evanno
Mireille Sevrin
Philip Janiak
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of NZ512981A publication Critical patent/NZ512981A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ512981A 1999-01-26 2000-01-21 Use of pyridazino[4,5-b]indole-1-acetamide derivatives for treating diseases related to the dysfunction of peripheral benzodiazepine receptors NZ512981A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9900806A FR2788696B1 (fr) 1999-01-26 1999-01-26 Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
PCT/FR2000/000135 WO2000044384A1 (fr) 1999-01-26 2000-01-21 UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1-ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AUX MALADIES LIEES AU DYSFONCTIONNEMENT DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES

Publications (1)

Publication Number Publication Date
NZ512981A true NZ512981A (en) 2002-10-25

Family

ID=9541212

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ512981A NZ512981A (en) 1999-01-26 2000-01-21 Use of pyridazino[4,5-b]indole-1-acetamide derivatives for treating diseases related to the dysfunction of peripheral benzodiazepine receptors

Country Status (32)

Country Link
US (1) US6395729B1 (xx)
EP (1) EP1148881B1 (xx)
JP (1) JP4688295B2 (xx)
KR (1) KR100694752B1 (xx)
CN (1) CN100577167C (xx)
AR (1) AR022413A1 (xx)
AT (1) ATE335487T1 (xx)
AU (1) AU764445B2 (xx)
BG (1) BG65152B1 (xx)
BR (1) BR0007718A (xx)
CA (1) CA2360754C (xx)
CO (1) CO5160242A1 (xx)
CY (1) CY1106257T1 (xx)
CZ (1) CZ294283B6 (xx)
DE (1) DE60029929T2 (xx)
DK (1) DK1148881T3 (xx)
EE (1) EE04905B1 (xx)
ES (1) ES2269097T3 (xx)
FR (1) FR2788696B1 (xx)
HK (1) HK1040905B (xx)
HU (1) HU228670B1 (xx)
IL (2) IL144181A0 (xx)
NO (1) NO321997B1 (xx)
NZ (1) NZ512981A (xx)
PL (1) PL193420B1 (xx)
PT (1) PT1148881E (xx)
RU (1) RU2243764C2 (xx)
SK (1) SK285707B6 (xx)
TR (1) TR200102134T2 (xx)
TW (1) TW541177B (xx)
UA (1) UA70349C2 (xx)
WO (1) WO2000044384A1 (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1329493A (zh) * 1998-12-02 2002-01-02 辉瑞产品公司 恢复p53家族蛋白质的构象稳定性的方法和组合物
FR2811897A1 (fr) * 2000-07-24 2002-01-25 Sanofi Synthelabo UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1- ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AU TRAITEMENT DES DYSFONCTIONNEMENTS DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES
FR2838124B1 (fr) 2002-04-03 2004-05-28 Sanofi Synthelabo Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique
FR2876715B1 (fr) 2004-10-19 2006-12-15 Profiles Du Ct Sa Embout de protection pour ecran de glissiere de securite routiere
GT200600005A (es) * 2005-01-12 2006-08-16 Un derivado de 2-(aminocarbonilo ciclico)-indolina y una composicion farmaceutica que lo contiene
WO2007086911A2 (en) * 2005-05-05 2007-08-02 Sanofi-Aventis U.S. Llc Stable nanoparticle formulations
PL1926476T3 (pl) * 2005-08-29 2013-08-30 Sanofi Aventis Us Llc Amorficzne stałe dyspersje 7-chloro-N,N,5-trimetylo-4-okso-3-fenylo-3,5-dihydro-4H-pirydazyno[4,5-b]indolo-1-acetamidu
EP1924585B1 (en) 2005-08-29 2011-11-02 Sanofi-Aventis U.S. LLC Novel crystalline form of a pyridazino [4 , 5-b] indole derivative
CN1946120B (zh) * 2006-10-20 2010-05-12 华为技术有限公司 实现话单关联的方法及系统
FR2918563B1 (fr) 2007-07-12 2009-12-04 Oreal Composition photoprotectrice fluide aqueuse a base d'un polymere polyamide a terminaison amide tertiaire.
FR2931064B1 (fr) 2008-05-14 2010-08-13 Oreal Composition cosmetique contenant un derive de dibenzoylmethane et un derive de pyrrolidinone; procede de photostabilisation du derive de dibenzoylmethane
AU2009283039A1 (en) * 2008-08-18 2010-02-25 Sanofi-Aventis U.S. Llc Process for preparing polymorph of 7-chloro-N, N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydr0-4H-pyridazin0[4,5-b]indole-1-acetamide
GB0818738D0 (en) * 2008-10-13 2008-11-19 Ge Healthcare Ltd Imaging neuroflammation
FR2936706B1 (fr) 2008-10-08 2010-12-17 Oreal Composition cosmetique contenant un derive de dibenzoylmethane et un compose dithiolane ; procede de photostabilisation du derive de dibenzoylmethane
EP2181717A1 (en) * 2008-10-28 2010-05-05 Sanofi-Aventis Use of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-B]indole-1-acetamide as a biomarker of peripheral benzodiazepine receptor levels
BR112012014661A2 (pt) 2009-12-18 2020-12-29 L'oreal Processo de tratamento cosmético da pele e conjunto cosmético
FR2960773B1 (fr) 2010-06-03 2015-12-11 Oreal Procedes de traitement cosmetique utilisant un revetement a base d'un polymere polyamide-polyether
WO2019113248A1 (en) * 2017-12-07 2019-06-13 The Regents Of The University Of California Anti-upar antibody-drug conjugates and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3121137A1 (de) * 1981-05-27 1982-12-16 Hoechst Ag, 6000 Frankfurt Neue pyridazino(4,5-b)indole, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen, zwischenprodukte und deren herstellung"
GB9411955D0 (en) * 1994-06-15 1994-08-03 Merck Sharp & Dohme Therapeutic agents
FR2754262B1 (fr) * 1996-10-08 1998-10-30 Synthelabo Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique
US6031120A (en) * 1997-07-29 2000-02-29 E. I. Du Pont De Nemours And Company Selective synthesis of organodiphosphite compounds
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788776B1 (fr) * 1999-01-26 2001-02-23 Synthelabo Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
CA2360754C (en) 2008-07-08
PL193420B1 (pl) 2007-02-28
TR200102134T2 (tr) 2003-03-21
IL144181A0 (en) 2002-05-23
FR2788696A1 (fr) 2000-07-28
AU764445B2 (en) 2003-08-21
DK1148881T3 (da) 2006-12-11
EP1148881A1 (fr) 2001-10-31
IL144181A (en) 2007-06-17
HUP0201280A3 (en) 2004-12-28
EP1148881B1 (fr) 2006-08-09
RU2243764C2 (ru) 2005-01-10
SK10502001A3 (sk) 2002-01-07
CO5160242A1 (es) 2002-05-30
ES2269097T3 (es) 2007-04-01
NO20013645L (no) 2001-09-26
BG105728A (en) 2002-02-28
WO2000044384A1 (fr) 2000-08-03
PL349364A1 (en) 2002-07-15
KR100694752B1 (ko) 2007-03-14
CY1106257T1 (el) 2011-06-08
NO321997B1 (no) 2006-07-31
NO20013645D0 (no) 2001-07-24
HK1040905B (zh) 2007-02-23
DE60029929T2 (de) 2007-08-30
ATE335487T1 (de) 2006-09-15
CA2360754A1 (en) 2000-08-03
UA70349C2 (en) 2004-10-15
JP4688295B2 (ja) 2011-05-25
EE200100388A (et) 2002-12-16
CZ294283B6 (cs) 2004-11-10
CN100577167C (zh) 2010-01-06
HK1040905A1 (en) 2002-06-28
AR022413A1 (es) 2002-09-04
DE60029929D1 (de) 2006-09-21
KR20010089624A (ko) 2001-10-06
CZ20012681A3 (cs) 2001-10-17
HUP0201280A2 (en) 2002-08-28
PT1148881E (pt) 2006-12-29
CN1344161A (zh) 2002-04-10
AU3057900A (en) 2000-08-18
TW541177B (en) 2003-07-11
HU228670B1 (en) 2013-05-28
US6395729B1 (en) 2002-05-28
BR0007718A (pt) 2001-11-13
SK285707B6 (sk) 2007-06-07
BG65152B1 (bg) 2007-04-30
EE04905B1 (et) 2007-10-15
JP2002535370A (ja) 2002-10-22
FR2788696B1 (fr) 2004-03-05

Similar Documents

Publication Publication Date Title
NZ512981A (en) Use of pyridazino[4,5-b]indole-1-acetamide derivatives for treating diseases related to the dysfunction of peripheral benzodiazepine receptors
GEP20063915B (en) PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
NZ514873A (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
DE69923849D1 (de) Quinolin-2-on-derivate verwendbar als antikrebsmittel
YU11501A (sh) Derivati 4,4,-biarilpiperidina sa aktivnošću na receptor opijata
BR0211305A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças ou condições e uso de um composto
NZ510629A (en) [1,2,4]Triazolo[1,5-c]pyrimidine derivatives and pharmaceutical use as adenosine A2A receptor antagonists
TW200635594A (en) Phenyl-piperazin methanone derivatives
WO2001012169A3 (en) Method of cancer treatment
CA2244777A1 (en) 2,3-benzodiazepine derivatives and their use as ampa-receptor inhibitors
IL110831A0 (en) Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
MXPA04000407A (es) Derivados de fenilacetamido-tiazol, procedimiento para su preparacion y uso como agentes antitumorales.
HUP0002650A2 (hu) 4-Oxo-3,5-dihidro-4H-piridazino[4,5-b]-indol-1-acetamid-származékok, eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
BG103684A (en) DERIVATIVES OF 2,3-DIHYDROFLUORO[3,2-b]PYRIDIN, METHOD FOR THEIR PREPARATION AND APPLICATION IN THERAPY
MX9706014A (es) Derivados de xanteno y acridina y su empleo.
AU3386299A (en) N-aryloxyethylamine derivatives for the treatment of depression
DE60111553D1 (de) Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
HK1018782A1 (en) 2,3-benzodiazepine derivatives their preparation as well as the intermediates and their use as medicaments
DK0850062T3 (da) Anvendelse af halofuginon til fremstilling af et medikament til svækkelse af neovaskularisering og til behandling af maligne tumorer hos mennesker
AU2287499A (en) Azetidinecarboxamide derivatives for treating cns disorders
HUP0402546A2 (hu) Szelektív foszfodiészteráz 4 inhibitor hatású pirazolo[3,4-c]-1,2,4-triazolo[4,3-alfa]piridin-származékok és adrenerg béta2-receptor agonista hatóanyagok kombinációi
MXPA98005355A (es) Derivados de 5-[(heteroaril) alquil]-3 -oxo-pirido [1, 2-a]bencimidazol -4-carboxamida utiles en el tratamiento de trastornos del sistema nervioso central.
ATE240329T1 (de) Zytotoxische pyrido(2,3,4-kl)acridinderivate, ihre herstellung und therapeutische verwendung
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired